{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:10:05Z","timestamp":1790237405405,"version":"4.1.0"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Biliary tract cancers (BTCs) are a heterogeneous group of tumors arising from cells in the bile ducts and gallbladder. The 5-year overall survival rate for all BTC stages combined is ~20%, and treatment options for patients with unresectable disease are limited, leaving an unmet clinical need. In recent years, significant efforts have been made to refine and implement targeted therapeutic approaches for patients with BTC. The adoption of early and comprehensive molecular profiling is crucial to identifying patients who may be candidates for effective targeted therapies. Characterization of the molecular landscape of BTCs led to the identification of murine double minute 2 homolog gene (MDM2) amplification across all BTC subtypes. The MDM2 protein is a critical negative regulator of p53 stabilization and activity that is an emerging actionable biomarker in BTCs. There are multiple therapeutic approaches that aim to target MDM2 activity, thereby restoring the intrinsic tumor suppressor function of p53 and halting oncogenesis. However, these have been limited by our evolving understanding of the role of MDM2 in BTC pathogenesis. Here, we offer a review of the current understanding of the role of MDM2 in BTC biology and its therapeutic implications.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf094","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:04Z","timestamp":1748345824000},"source":"Crossref","is-referenced-by-count":3,"title":["MDM2 as a therapeutic target in advanced biliary tract cancers"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-3439","authenticated-orcid":false,"given":"Kristen R","family":"Spencer","sequence":"first","affiliation":[{"name":"Department of Medicine at NYU Grossman School of Medicine, NYU Langone Perlmutter Cancer Center , New York, NY 10016 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-8802","authenticated-orcid":false,"given":"Gentry G","family":"King","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington , Seattle, WA 98109 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2025052707365646700_CIT0001","doi-asserted-by":"publisher","first-page":"100378","DOI":"10.1016\/j.esmoop.2021.100378","article-title":"How I treat biliary tract cancer","volume":"7","author":"Lamarca","year":"2022","journal-title":"ESMO Open"},{"key":"2025052707365646700_CIT0002","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1186\/s12876-022-02637-8","article-title":"The epidemiological trends of biliary tract cancers in the United States of America","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2025052707365646700_CIT0003","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1158\/1055-9965.EPI-21-0265","article-title":"Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race\/ethnicity, and stage at diagnosis: United States, 2013 to 2017","volume":"30","author":"Ellington","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2025052707365646700_CIT0004","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"2025052707365646700_CIT0005","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025052707365646700_CIT0006","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.3390\/curroncol30070507","article-title":"Ampullary cancer: histological subtypes, markers, and clinical behaviour-state of the art and perspectives","volume":"30","author":"Nappo","year":"2023","journal-title":"Curr Oncol"},{"key":"2025052707365646700_CIT0007","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2217\/fon-2021-1302","article-title":"Second-line treatments in advanced biliary tract cancer: systematic literature review of efficacy, effectiveness and safety","volume":"18","author":"Khankhel","year":"2022","journal-title":"Future Oncol"},{"key":"2025052707365646700_CIT0008","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/PAS.0000000000001006","article-title":"MDM2 amplification in intrahepatic cholangiocarcinomas: its relationship with large-duct type morphology and uncommon KRAS mutations","volume":"42","author":"Kim","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"2025052707365646700_CIT0009","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J Hepatol"},{"key":"2025052707365646700_CIT0010","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.21037\/jgo-21-776","article-title":"Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma","volume":"12","author":"Zheng","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"2025052707365646700_CIT0011","doi-asserted-by":"publisher","first-page":"153116","DOI":"10.1016\/j.prp.2020.153116","article-title":"Target molecular treatment markers in intrahepatic cholangiocarcinoma based on Chinese population","volume":"216","author":"Pu","year":"2020","journal-title":"Pathol Res Pract"},{"key":"2025052707365646700_CIT0012","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1200\/po.20.00487","article-title":"Unraveling neuroendocrine gallbladder cancer: comprehensive clinicopathologic and molecular characterization","volume":"5","author":"de Bitter","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"2025052707365646700_CIT0013","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1158\/1078-0432.CCR-22-1954","article-title":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","volume":"28","author":"Giraldo","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025052707365646700_CIT0014","doi-asserted-by":"publisher","first-page":"1176935120922154","DOI":"10.1177\/1176935120922154","article-title":"Identification of altered genes in gallbladder cancer as potential driver mutations for diagnostic and prognostic purposes: a computational approach","volume":"19","author":"D\u2019Afonseca","year":"2020","journal-title":"Cancer Inform"},{"key":"2025052707365646700_CIT0015","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cncr.31951","article-title":"Ampullary cancer: Evaluation of somatic and germline genetic alterations and association with clinical outcomes","volume":"125","author":"Wong","year":"2019","journal-title":"Cancer"},{"key":"2025052707365646700_CIT0016","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2025052707365646700_CIT0017","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025052707365646700_CIT0018","doi-asserted-by":"publisher","first-page":"100226","DOI":"10.1016\/j.jhepr.2021.100226","article-title":"Cell of origin in biliary tract cancers and clinical implications","volume":"3","author":"Moeini","year":"2021","journal-title":"JHEP Rep"},{"key":"2025052707365646700_CIT0019","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12253-018-0491-8","article-title":"Cholangiocarcinoma: classification, histopathology and molecular carcinogenesis","volume":"26","author":"Lendvai","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2025052707365646700_CIT0020","doi-asserted-by":"publisher","first-page":"457","DOI":"10.21037\/hbsn-23-215","article-title":"The promise of precision medicine: how biomarkers are shaping the future of cholangiocarcinoma treatment","volume":"12","author":"Macias","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025052707365646700_CIT0021","doi-asserted-by":"publisher","first-page":"967472","DOI":"10.1155\/2015\/967472","article-title":"Gallbladder cancer in the 21st century","volume":"2015","author":"Kanthan","year":"2015","journal-title":"J Oncol"},{"key":"2025052707365646700_CIT0022","doi-asserted-by":"publisher","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2025052707365646700_CIT0023","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"key":"2025052707365646700_CIT0024","doi-asserted-by":"publisher","first-page":"10732748231211764","DOI":"10.1177\/10732748231211764","article-title":"Short-and long-term survival of metastatic biliary tract cancer in the United States","volume":"30","author":"Nghiem","year":"2023","journal-title":"Cancer Control"},{"key":"2025052707365646700_CIT0025","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1186\/s12885-022-10286-z","article-title":"Epidemiologic patterns of biliary tract cancer in the United States: 2001\u20132015","volume":"22","author":"Koshiol","year":"2022","journal-title":"BMC Cancer"},{"key":"2025052707365646700_CIT0026","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.annonc.2024.05.285","article-title":"279MO Three-year survival, safety and extended long-term survivor (eLTS) analysis from the phase III TOPAZ-1 study of durvalumab (D) plus chemotherapy in biliary tract cancer (BTC)","volume":"35","author":"Oh","year":"2024","journal-title":"Ann Oncol"},{"key":"2025052707365646700_CIT0027","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"2025052707365646700_CIT0028","doi-asserted-by":"publisher","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"2025052707365646700_CIT0029","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat Genet"},{"key":"2025052707365646700_CIT0030","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov"},{"key":"2025052707365646700_CIT0031","volume-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Biliary Tract Cancers V.5.2024","year":"2024"},{"key":"2025052707365646700_CIT0032","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1080\/14796694.2024.2340959","article-title":"Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians\u2019 and patients\u2019 perspectives","volume":"20","author":"Shroff","year":"2024","journal-title":"Fut Oncol"},{"key":"2025052707365646700_CIT0033","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_1.s3","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann Oncol"},{"key":"2025052707365646700_CIT0034","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/jco.2022.40.16_suppl.3004","article-title":"A phase Ia\/Ib, dose-escalation\/expansion study of the MDM2\u2013p53 antagonist BI 907828 in patients with solid tumors, including advanced\/metastatic liposarcoma (LPS)","volume":"40","author":"Gounder","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025052707365646700_CIT0035","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.molcel.2006.01.020","article-title":"p53 ubiquitination: Mdm2 and beyond","volume":"21","author":"Brooks","year":"2006","journal-title":"Mol Cell"},{"key":"2025052707365646700_CIT0036","doi-asserted-by":"publisher","first-page":"188556","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2025052707365646700_CIT0037","doi-asserted-by":"publisher","first-page":"1006959","DOI":"10.3389\/fonc.2022.1006959","article-title":"Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma","volume":"12","author":"Traweek","year":"2022","journal-title":"Front Oncol"},{"key":"2025052707365646700_CIT0038","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3389\/fphar.2020.00631","article-title":"Targeting mouse double minute 2: current concepts in DNA damage repair and therapeutic approaches in cancer","volume":"11","author":"Li","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025052707365646700_CIT0039","doi-asserted-by":"publisher","first-page":"22109","DOI":"10.3390\/ijms151222109","article-title":"Battle against cancer: an everlasting saga of p53","volume":"15","author":"Hao","year":"2014","journal-title":"Int J Mol Sci"},{"key":"2025052707365646700_CIT0040","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.17.00235","article-title":"Analysis of MDM2 amplification: next-generation sequencing of patients with diverse malignancies","volume":"2","author":"Kato","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2025052707365646700_CIT0041","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","article-title":"The first 30 years of p53: growing ever more complex","volume":"9","author":"Levine","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2025052707365646700_CIT0042","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"2025052707365646700_CIT0043","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1128\/MCB.19.3.1751","article-title":"Regulation of p53 function and stability by phosphorylation","volume":"19","author":"Ashcroft","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2025052707365646700_CIT0044","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12935-019-0937-4","article-title":"The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors","volume":"19","author":"Hou","year":"2019","journal-title":"Cancer Cell Int"},{"key":"2025052707365646700_CIT0045","doi-asserted-by":"publisher","first-page":"33232","DOI":"10.18632\/oncotarget.26075","article-title":"Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic","volume":"9","author":"Dembla","year":"2018","journal-title":"Oncotarget"},{"key":"2025052707365646700_CIT0046","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.1038\/s41467-021-26213-y","article-title":"Cancer gene mutation frequencies for the US population","volume":"12","author":"Mendiratta","year":"2021","journal-title":"Nat Commun"},{"key":"2025052707365646700_CIT0047","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3390\/biom10111474","article-title":"Targeting P53 as a future strategy to overcome gemcitabine resistance in biliary tract cancers","volume":"10","author":"Wu","year":"2020","journal-title":"Biomolecules"},{"key":"2025052707365646700_CIT0048","doi-asserted-by":"publisher","first-page":"TPS3165","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3165","article-title":"A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)","volume":"40","author":"Dumbrava","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025052707365646700_CIT0049","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.2217\/fon-2023-0963","article-title":"Brightline-2: a phase IIa\/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors","volume":"20","author":"Yoo","year":"2024","journal-title":"Future Oncol"},{"key":"2025052707365646700_CIT0050","doi-asserted-by":"publisher","first-page":"TPS4179","DOI":"10.1200\/jco.2023.41.16_suppl.tps4179","article-title":"A phase IIa\/IIb, open-label trial of BI 907828, an MDM2\u2013p53 antagonist, in patients with locally advanced\/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2","volume":"41","author":"Goyal","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025052707365646700_CIT0051","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A first-in-human phase I study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025052707365646700_CIT0052","doi-asserted-by":"publisher","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and rxtrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025052707365646700_CIT0053","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/1538-7445.am2022-82","article-title":"Molecular characterization of gallbladder cancer","volume":"82","author":"Giraldo","year":"2022","journal-title":"Cancer Res"},{"key":"2025052707365646700_CIT0054","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/hep.31585","article-title":"Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer","volume":"73","author":"Br\u00e4gelmann","year":"2021","journal-title":"Hepatology"},{"key":"2025052707365646700_CIT0055","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/ott.s440979","article-title":"Efficacy and safety of the MDM2\u2013p53 antagonist brigimadlin (BI 907828) in patients with advanced biliary tract cancer: a case series","volume":"17","author":"Yamamoto","year":"2024","journal-title":"OncoTargets Ther"},{"key":"2025052707365646700_CIT0056","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.2147\/OTT.S172315","article-title":"MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)","volume":"12","author":"Khurana","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2025052707365646700_CIT0057","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 inhibitors for cancer therapy: the past, present, and future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol Rev"},{"key":"2025052707365646700_CIT0058","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fonc.2016.00007","article-title":"Clinical overview of MDM2\/X-targeted therapies","volume":"6","author":"Burgess","year":"2016","journal-title":"Front Oncol"},{"key":"2025052707365646700_CIT0059","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"2025052707365646700_CIT0060","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025052707365646700_CIT0061","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1021\/ml4000657","article-title":"Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development","volume":"4","author":"Vu","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"2025052707365646700_CIT0062","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025052707365646700_CIT0063","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025052707365646700_CIT0064","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"2025052707365646700_CIT0065","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.exphem.2013.11.012","article-title":"Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis","volume":"42","author":"Iancu-Rubin","year":"2014","journal-title":"Exp Hematol"},{"key":"2025052707365646700_CIT0066","doi-asserted-by":"publisher","first-page":"5855","DOI":"10.1158\/0008-5472.CAN-14-0799","article-title":"SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression","volume":"74","author":"Wang","year":"2014","journal-title":"Cancer Res"},{"key":"2025052707365646700_CIT0067","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1158\/1078-0432.CCR-15-1522","article-title":"SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma","volume":"22","author":"Bill","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025052707365646700_CIT0068","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2017.02.005","article-title":"A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours","volume":"76","author":"de Jonge","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025052707365646700_CIT0069","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14656566.2019.1618271","article-title":"Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments","volume":"20","author":"Suarez-Kelly","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2025052707365646700_CIT0070","author":"Rain Therapeutics","year":"2022"},{"key":"2025052707365646700_CIT0071","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12094-019-02158-z","article-title":"Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification","volume":"22","author":"Cornillie","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"2025052707365646700_CIT0072","doi-asserted-by":"publisher","first-page":"S472","DOI":"10.1016\/j.annonc.2023.09.1859","article-title":"A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2\u2013p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours","volume":"34","author":"Sch\u00f6ffski","year":"2023","journal-title":"Ann Oncol"},{"key":"2025052707365646700_CIT0073","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2024.42.3_suppl.487","article-title":"Efficacy and safety of brigimadlin (BI 907828), an MDM2\u2013p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia\/Ib dose-escalation\/expansion trials","volume":"42","author":"Macarulla","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025052707365646700_CIT0074","author":"ClinicalTrials.gov","year":"2022"},{"key":"2025052707365646700_CIT0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.9506","article-title":"Navtemadlin (KRT-232) activity after failure of anti-PD-1\/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC)","author":"Wong","year":"2022"},{"key":"2025052707365646700_CIT0076","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"key":"2025052707365646700_CIT0077","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","article-title":"MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment","volume":"7","author":"Fang","year":"2019","journal-title":"J ImmunoTher Cancer"},{"key":"2025052707365646700_CIT0078","doi-asserted-by":"publisher","first-page":"e9986","DOI":"10.1097\/MD.0000000000009986","article-title":"Pleomorphic liposarcoma: an analysis of 6 case reports and literature review","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"2025052707365646700_CIT0079","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1158\/1538-7445.am2018-4866","article-title":"Abstract 4866: BI 907828: a novel, potent MDM2 inhibitor that induces antitumor immunologic memory and acts synergistically with an anti-PD-1 antibody in syngeneic mouse models of cancer","volume":"78","author":"Rudolph","year":"2018","journal-title":"Cancer Res"},{"key":"2025052707365646700_CIT0080","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12935-024-03356-8","article-title":"MDM2: current research status and prospects of tumor treatment","volume":"24","author":"Yao","year":"2024","journal-title":"Cancer Cell Int"},{"key":"2025052707365646700_CIT0081","volume-title":"AbbVie Inc","author":"VENCLEXTA\u00ae Prescribing Information"},{"key":"2025052707365646700_CIT0082","author":"ClinicalTrials.gov","year":"2019"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf094\/63370855\/oyaf094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf094\/63370855\/oyaf094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:37:06Z","timestamp":1748345826000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf094\/8151390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf094","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf094"}}